All‐cause mortality · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Blood ammonia concentrations (units unspecified) · adults with cirrhosis and hepatic encephalopathy
3 findings from 1 review
no estimate extracted
1 study · 35 participants
Very low
no estimate extracted
1 study · 16 participants
Very low
no estimate extracted
1 study · 231 participants
Very low
Blood ammonia concentrations (µmol/L*week) · adults with cirrhosis and hepatic encephalopathy
2 findings from 1 review
Hepatic encephalopathy · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Health‐related quality of life · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Plasma ammonia concentration (µmol/L) · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
1 finding from 1 review
Clinical non‐response at post‐treatment · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes clinical non‐response at post‐treatment compared with other psychological therapies (very low certainty).
1 finding from 1 review
Clinical non‐response at · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes clinical non‐response at compared with other psychological therapies (very low certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes treatment acceptability at post‐treatment Dropout rates compared with other psychological therapies (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes treatment acceptability at compared with other psychological therapies (very low certainty).
1 finding from 1 review
Clinical non‐remission at post‐treatment · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes non‐remission at post‐treatment compared with other psychological therapies (very low certainty).
1 finding from 1 review
Depression levels at post‐treatment (HAM‐D) · patients with depression
1 finding from 1 review
Depression levels at · patients with depression
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Radiotherapy (morning) showed no clear difference in oral mucositis (moderate to severe) compared with radiotherapy (afternoon/evening); GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
1 finding from 1 review
no estimate extracted
2 studies
GRADE not reported